Analysis of microarray-identified genes and MicroRNAs associated with Trifluridine resistance in colorectal cancer

References

• Bandettini WP, Kellman P, Mancini C, Booker OJ, Vasu S, Leung SW, Wilson JR, Shanbhag SM, Chen MY, Arai AE. 2012. Multicontrast delayed enhancement (MCODE) improves detection of subendocardial myocardial infarction by late gadolinium enhancement cardiovascular magnetic resonance: a clinical validation study. J Cardiovasc Magn Reson. 14:83. doi:10.1186/1532-429X-14-83.
   PubMed Web of Science ®Google Scholar
• Baretti M, Rimassa L, Personeni N, Giordano L, Tronconi MC, Pressiani T, Bozzarelli S, Santoro A. 2018. Effect of comorbidities in stage II/III colorectal cancer patients treated with surgery and neoadjuvant/adjuvant chemotherapy: a single-center, observational study. Clin Colorectal Cancer. 17:e489–e498. doi:10.1016/j.clcc.2018.03.010.
   PubMed Web of Science ®Google Scholar
• Barrett T, Suzek TO, Troup DB, Wilhite SE, Ngau WC, Ledoux P, Rudnev D, Lash AE, Fujibuchi W, Edgar R. 2005. NCBI GEO: mining millions of expression profiles–database and tools. Nucleic Acids Res. 33:D562–D566. doi:10.1093/nar/gki022.
   PubMed Web of Science ®Google Scholar
• Bayraktar R, Van Roosbroeck K. 2018. miR-155 in cancer drug resistance and as target for miRNA-based therapeutics. Cancer Metastasis Rev. 37:33–44. doi:10.1007/s10555-017-9724-7.
   PubMed Web of Science ®Google Scholar
• Cao C, Vasilatos SN, Bhargava R, Fine JL, Oesterreich S, Davidson NE, Huang Y. 2017. Functional interaction of histone deacetylase 5 (HDAC5) and lysine-specific demethylase 1 (LSD1) promotes breast cancer progression. Oncogene. 36:133–145. doi:10.1038/onc.2016.186.
   PubMed Web of Science ®Google Scholar
• Collins FS, Varmus H. 2015. A new initiative on precision medicine. N Engl J Med. 372:793–795. doi:10.1056/NEJMp1500523.
   PubMed Web of Science ®Google Scholar
• Colomer C, Margalef P, Villanueva A, Vert A, Pecharroman I, Solé L, González-Farré M, Alonso J, Montagut C, Martinez-Iniesta M, et al. 2019. IKKα kinase regulates the DNA damage response and drives chemo-resistance in cancer. Mol Cell. 75:669–682.e665. doi:10.1016/j.molcel.2019.05.036.
   PubMed Web of Science ®Google Scholar
• De Angelis PM, Fjell B, Kravik KL, Haug T, Tunheim SH, Reichelt W, Beigi M, Clausen OP, Galteland E, Stokke T. 2004. Molecular characterizations of derivatives of HCT116 colorectal cancer cells that are resistant to the chemotherapeutic agent 5-fluorouracil. Int J Oncol. 24:1279–1288.
   PubMed Web of Science ®Google Scholar
• Dweep H, Gretz N. 2015. miRWalk2. 0: a comprehensive atlas of microRNA-target interactions. Nat Methods. 12:697. doi:10.1038/nmeth.3485.
   PubMed Web of Science ®Google Scholar
• Eberlé D, Hegarty B, Bossard P, Ferré P, Foufelle F. 2004. SREBP transcription factors: master regulators of lipid homeostasis. Biochimie. 86:839–848. doi:10.1016/j.biochi.2004.09.018.
   PubMed Web of Science ®Google Scholar
• Edahiro K, Iimori M, Kobunai T, Morikawa-Ichinose T, Miura D, Kataoka Y, Niimi S, Wakasa T, Saeki H, Oki E, et al. 2018. Thymidine kinase 1 loss confers Trifluridine resistance without affecting 5-fluorouracil metabolism and cytotoxicity. Mol Cancer Res. 16:1483–1490. doi:10.1158/1541-7786.
   PubMed Web of Science ®Google Scholar
• Fakih MG. 2015. Metastatic colorectal cancer: current state and future directions. J Clin Oncol. 33:1809–1824. doi:10.1200/JCO.2014.59.7633.
   PubMed Web of Science ®Google Scholar
• Falzone L, Scola L, Zanghì A, Biondi A, Di Cataldo A, Libra M, Candido S. 2018. Integrated analysis of colorectal cancer microRNA datasets: identification of microRNAs associated with tumor development. Aging (Milano). 10:1000–1014. doi:10.18632/aging.101444.
   Google Scholar
• Fan CW, Kuo YB, Lin GP, Chen SM, Chang SH, Li BA, Chan EC. 2017. Development of a multiplexed tumor-associated autoantibody-based blood test for the detection of colorectal cancer. Clin Chim Acta. 475:157–163. doi:10.1016/j.cca.2017.10.022.
   PubMed Web of Science ®Google Scholar
• Fararjeh AS, Liu YN. 2019. ZBTB46, SPDEF, and ETV6: novel potential biomarkers and therapeutic targets in castration-resistant prostate cancer. Int J Mol Sci. 20:2802. doi:10.3390/ijms20112802.
   PubMed Web of Science ®Google Scholar
• Fu J, Qiu H, Cai M, Pan Y, Cao Y, Liu L, Yun J, Zhang CZ. 2013. Low cyclin F expression in hepatocellular carcinoma associates with poor differentiation and unfavorable prognosis. Cancer Sci. 104:508–515. doi:10.1111/cas.12100.
   PubMed Web of Science ®Google Scholar
• Ghanbarian M, Afgar A, Yadegarazari R, Najafi R, Teimoori-Toolabi L. 2018. Through oxaliplatin resistance induction in colorectal cancer cells, increasing ABCB1 level accompanies decreasing level of miR-302c-5p, miR-3664-5p and miR-129-5p. Biomed Pharmacother. 108:1070–1080. doi:10.1016/j.biopha.2018.09.112.
   PubMed Web of Science ®Google Scholar
• Guang MHZ, McCann A, Bianchi G, Zhang L, Dowling P, Bazou D, O'Gorman P, Anderson KC. 2018. Overcoming multiple myeloma drug resistance in the era of cancer ‘omics’. Leuk Lymphoma. 59:542–561. doi:10.1080/10428194.2017.1337115.
   PubMed Web of Science ®Google Scholar
• Guo H, Zeng D, Zhang H, Bell T, Yao J, Liu Y, Huang S, Li CJ, Lorence E, Zhou S, et al. 2019. Dual inhibition of PI3K signaling and histone deacetylation halts proliferation and induces lethality in mantle cell lymphoma. Oncogene. 38:1802–1814. doi:10.1038/s41388-018-0550-3.
   PubMed Web of Science ®Google Scholar
• Hao J, Huang K, Chen C, Liang Y, Wang Y, Zhang X, Huang H. 2018. Polydatin improves glucose and lipid metabolisms in insulin-resistant HepG2 cells through the AMPK pathway. Biol Pharm Bull. 41:891–898. doi:10.1248/bpb.b17-01027.
   PubMed Web of Science ®Google Scholar
• Huang WT, Tsai YH, Chen SH, Kuo CW, Kuo YL, Lee KT, Chen WC, Wu PC, Chuang CY, Cheng SM, et al. 2017. HDAC2 and HDAC5 up-regulations modulate survivin and miR-125a-5p expressions and promote hormone therapy resistance in estrogen receptor positive breast cancer cells. Front Pharmacol. 8:902. doi:10.3389/fphar.2017.00902.
   PubMed Web of Science ®Google Scholar
• Kandhavelu J, Subramanian K, Khan A, Omar A, Ruff P, Penny C. 2018. Computational analysis of miRNA and their gene targets significantly involved in colorectal cancer progression. MicroRNA. 8:68–75. doi:10.2174/2211536607666180803100246.
   Google Scholar
• Lin YL, Liu KL, Lin BR. 2020. Trifluridine/tipiracil in combination with local therapy may be a favorable option for refractory metastatic colorectal cancer patients: A case report. Medicine (Baltimore). 99:e22780. doi:10.1097/md.0000000000022780.
   PubMed Web of Science ®Google Scholar
• Liu H, Wang S, Zhou S, Meng Q, Ma X, Song X, Wang L, Jiang W. 2019. Drug resistance-related competing interactions of lncRNA and mRNA across 19 cancer types. Mol Ther Nucleic Acids. 16:442–451. doi:10.1016/j.omtn.2019.03.011.
   PubMedGoogle Scholar
• Liu J, Gu J, Feng Z, Yang Y, Zhu N, Lu W, Qi F. 2016. Both HDAC5 and HDAC6 are required for the proliferation and metastasis of melanoma cells. J Transl Med. 14:7. doi:10.1186/s12967-015-0753-0.
   PubMed Web of Science ®Google Scholar
• Masuishi T, Taniguchi H, Hamauchi S, Komori A, Kito Y, Narita Y, Tsushima T, Ishihara M, Todaka A, Tanaka T, et al. 2017. Regorafenib versus Trifluridine/tipiracil for refractory metastatic colorectal cancer: a retrospective comparison. Clin Colorectal Cancer. 16:e15–e22. doi:10.1016/j.clcc.2016.07.019.
   PubMed Web of Science ®Google Scholar
• Moriwaki T, Fukuoka S, Taniguchi H, Takashima A, Kumekawa Y, Kajiwara T, Yamazaki K, Esaki T, Makiyama C, Denda T, et al. 2018. Propensity score analysis of Regorafenib versus Trifluridine/tipiracil in patients with metastatic colorectal cancer refractory to standard chemotherapy (REGOTAS): a Japanese society for cancer of the colon and rectum multicenter observational study. Oncologist. 23:7–15. doi:10.1634/theoncologist.2017-0275.
   PubMed Web of Science ®Google Scholar
• Murakami Y, Kazuno H, Emura T, Tsujimoto H, Suzuki N, Fukushima M. 2000. Different mechanisms of acquired resistance to fluorinated pyrimidines in human colorectal cancer cells. Int J Oncol. 17:277–283. doi:10.3892/ijo.17.2.277.
   PubMed Web of Science ®Google Scholar
• Perone Y, Farrugia AJ, Rodríguez-Meira A, Győrffy B, Ion C, Uggetti A, Chronopoulos A, Marrazzo P, Faronato M, Shousha S, et al. 2019. SREBP1 drives keratin-80-dependent cytoskeletal changes and invasive behavior in endocrine-resistant ERα breast cancer. Nat Commun. 10:2115. doi:10.1038/s41467-019-09676-y.
   PubMed Web of Science ®Google Scholar
• Rasighaemi P, Ward AC. 2017. ETV6 and ETV7: siblings in hematopoiesis and its disruption in disease. Crit Rev Oncol Hematol. 116:106–115. doi:10.1016/j.critrevonc.2017.05.011.
   PubMed Web of Science ®Google Scholar
• Reiner Z. 2014. Resistance and intolerance to statins. Nutr Metab Cardiovasc Dis. 24:1057–1066. doi:10.1016/j.numecd.2014.05.009.
   PubMed Web of Science ®Google Scholar
• Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, Smyth GK. 2015. Limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 43:e47. doi:10.1093/nar/gkv007.
   PubMed Web of Science ®Google Scholar
• Seyhan AA, Varadarajan U, Choe S, Liu W, Ryan TE. 2012. A genome-wide RNAi screen identifies novel targets of neratinib resistance leading to identification of potential drug resistant genetic markers. Mol BioSyst. 8:1553–1570. doi:10.1039/c2mb05512k.
   PubMed Web of Science ®Google Scholar
• Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, Amin N, Schwikowski B, Ideker T. 2003. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 13:2498–2504. doi:10.1101/gr.1239303.
   PubMed Web of Science ®Google Scholar
• Si W, Shen J, Zheng H, Fan W. 2019. The role and mechanisms of action of microRNAs in cancer drug resistance. Clin Epigenetics. 11:25. doi:10.1186/s13148-018-0587-8.
   PubMed Web of Science ®Google Scholar
• Slotta-Huspenina J, Drecoll E, Feith M, Habermehl D, Combs S, Weichert W, Bettstetter M, Becker K, Langer R. 2018. MicroRNA expression profiling for the prediction of resistance to neoadjuvant radiochemotherapy in squamous cell carcinoma of the esophagus. J Transl Med. 16:109. doi:10.1186/s12967-018-1492-9.
   PubMed Web of Science ®Google Scholar
• Sun X, Wang X, Feng W, Guo H, Tang C, Lu Y, Xiang X, Bao Y. 2017. Gene signatures associated with drug resistance to irinotecan and oxaliplatin predict a poor prognosis in patients with colorectal cancer. Oncol Lett. 13:2089–2096. doi:10.3892/ol.2017.5691.
   PubMed Web of Science ®Google Scholar
• Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. 2021. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 71:209–249. doi:10.3322/caac.21660.
   PubMed Web of Science ®Google Scholar
• Szklarczyk D, Franceschini A, Kuhn M, Simonovic M, Roth A, Minguez P, Doerks T, Stark M, Muller J, Bork P, et al. 2011. The STRING database in 2011: functional interaction networks of proteins, globally integrated and scored. Nucleic Acids Res. 39:D561–D568. doi:10.1093/nar/gkq973.
   PubMed Web of Science ®Google Scholar
• Tang J, Ma W, Zeng Q, Tan J, Cao K, Luo L. 2019. Identification of miRNA-based signature as a novel potential prognostic biomarker in patients with breast cancer. Dis Markers. 2019:3815952. doi:10.1155/2019/3815952.
   PubMed Web of Science ®Google Scholar
• Tsai YC, Zeng T, Abou-Kheir W, Yeh HL, Yin JJ, Lee YC, Chen WY, Liu YN. 2018. Disruption of ETV6 leads to TWIST1-dependent progression and resistance to epidermal growth factor receptor tyrosine kinase inhibitors in prostate cancer. Mol Cancer. 17:42. doi:10.1186/s12943-018-0785-1.
   PubMed Web of Science ®Google Scholar
• Tsunekuni K, Konno M, Asai A, Koseki J, Kobunai T, Takechi T, Doki Y, Mori M, Ishii H. 2017. MicroRNA profiles involved in Trifluridine resistance. Oncotarget. 8:53017–53027. doi:10.18632/oncotarget.18078.
   PubMedGoogle Scholar
• Van der Jeught K, Xu HC, Li YJ, Lu XB, Ji G. 2018. Drug resistance and new therapies in colorectal cancer. World J Gastroenterol. 24:3834–3848. doi:10.3748/wjg.v24.i34.3834.
   PubMed Web of Science ®Google Scholar
• Wagner AH, Coffman AC, Ainscough BJ, Spies NC, Skidmore ZL, Campbell KM, Krysiak K, Pan D, McMichael JF, Eldred JM, et al. 2016. DGIdb 2.0: mining clinically relevant drug–gene interactions. Nucleic Acids Res. 44:D1036–D1044. doi:10.1093/nar/gkv1165.
   PubMed Web of Science ®Google Scholar
• Xue Y, Lian W, Zhi J, Yang W, Li Q, Guo X, Gao J, Qu H, Lin W, Li Z, et al. 2019. HDAC5-mediated deacetylation and nuclear localisation of SOX9 is critical for tamoxifen resistance in breast cancer. Br J Cancer. 121:1039–1049. doi:10.1038/s41416-019-0625-0.
   PubMed Web of Science ®Google Scholar
• Yang L, Zhang L, Lu L, Wang Y. 2020. lncRNA increases proliferation and multidrug resistance of retinoblastoma cells through downregulating miR-513a-5p. DNA Cell Biol. 39:69–77. doi:10.1089/dna.2019.5063.
   PubMed Web of Science ®Google Scholar
• Yu G, Wang L, Han Y, He Q. 2012. Clusterprofiler: an R package for comparing biological themes among gene clusters. OMICS. 16:284–287. doi:10.1089/omi.2011.0118.
   PubMed Web of Science ®Google Scholar
• Zhao D, Zhao X, Li W. 2020. Identification of differentially expressed metastatic genes and their signatures to predict the overall survival of uveal melanoma patients by bioinformatics analysis. Int J Ophthalmol. 13:1046–1053. doi:10.18240/ijo.2020.07.05.
   PubMed Web of Science ®Google Scholar
• Zhao L, Jiang L, He L, Wei Q, Bi J, Wang Y, Yu L, He M, Zhao L, Wei M. 2019. Identification of a novel cell cycle-related gene signature predicting survival in patients with gastric cancer. J Cell Physiol. 234:6350–6360. doi:10.1002/jcp.27365.
   PubMed Web of Science ®Google Scholar
• Zhou SS, Jin JP, Wang JQ, Zhang ZG, Freedman JH, Zheng Y, Cai L. 2018. miRNAS in cardiovascular diseases: potential biomarkers, therapeutic targets and challenges. Acta Pharmacol Sin. 39:1073–1084. doi:10.1038/aps.2018.30.
   PubMed Web of Science ®Google Scholar